Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Forty Seven nets $81mm in public offering

Executive Summary

Oncology firm Forty Seven Inc. netted $81mm through a public offering of 10.78mm common shares (including the overallotment) at $8. Funds will support continued development of lead candidate 5F9, an anti-CD47 antibody in various clinical trials for solid and blood cancers. Earlier this month, Ono licensed exclusive rights to develop and sell 5F9 in Japan, South Korea, Taiwan, and the ASEAN countries.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

UsernamePublicRestriction

Register